XtalPi Holdings Limited (2228.HK), the AI and robotics-driven R&D platform, today announced the successful development of two innovative topical active ingredients for hair growth and retention: the small molecule Remeanagen™ (XTP-118) and the peptide AquaKine™ (XTP-016).
The combination formula featuring these “Twin-Star” molecules demonstrated unique advantages in efficacy, speed of onset, and safety across multi-dimensional validation studies, offering a potential breakthrough for the global hair loss epidemic, which affects over 2.5 billion people worldwide.
Global Market Ready and Regulatory Status
- Both molecules have successfully obtained registration in the International Nomenclature of Cosmetic Ingredients (INCI) Directory.
- The co-formulation has completed Facility Registration and Product Listing with the U.S. Food and Drug Administration (FDA) via XtalPi’s incubated consumer brand, Groland, and is set for launch in overseas markets.
- Domestic ingredient filing in China is currently being accelerated.
AI’s Solution to a Persistent Biomedical Challenge
Existing consumer hair loss products often suffer from low user response rates, risk of initial shedding, and systemic side effects due to poorly understood mechanisms. XtalPi’s platform, originating from MIT, addressed these challenges by targeting core biological pathways and biomarkers critical to the hair growth cycle.
The breakthrough was achieved by tackling three core challenges in molecular design:
- “Penetrate”: High-Efficiency Delivery: The AI platform optimized Remeanagen™ and AquaKine™ to achieve superior transdermal absorption, enabling the ingredients to effectively penetrate the scalp barrier—a major hurdle for topical treatments.
- “Activate”: Awakening Dormant Follicles: Remeanagen™ (XTP-118), discovered through AI exploration of novel chemical space, works by effectively activating dormant hair follicle stem cells to enter the growth phase and significantly extending this cycle.
- “Nourish”: Consolidating Growth: AquaKine™ (XTP-016) was designed to optimize the microenvironment for long-term follicle health by promoting the proliferation of key cells and boosting the production of growth-supportive proteins like collagen and elastin.
Exceptional Efficacy and Safety Profile
Human efficacy testing and extensive real-world consumer trials demonstrated the formula’s competitive edge (data from Groland and third-party testing institutions):
- Rapid Onset: Subjects observed initial improvements in anagen (growth phase) follicle density in as fast as 14 days.
- Significant Results: After 45 days of use, over 90% of subjects observed visible increases in hair density. Average hair shedding was reduced by 33% to 45%.
- High Safety: The formula showed an excellent safety profile. Crucially, in a large set of human efficacy tests and nearly a hundred real-world use cases, the formula did not cause the common adverse reactions, such as initial shedding, often associated with existing products.
Powered by XtalPi’s Proven AI Engine
The development of Remeanagen™ and AquaKine™ utilized XtalPi’s decade-long, multi-billion dollar investment in its ID4 AI Molecular Development Platform. This platform’s predictive, design, and optimization capabilities have been validated through multiple high-profile collaborations, including:
- Empowering Pfizer’s rapid development of the COVID-19 oral antiviral Paxlovid®.
- Securing major AI small molecule and biologics partnerships with Eli Lilly.
- Aiding the development of SIGX1094, a breakthrough candidate for diffuse gastric cancer that received a Prix Galien USA nomination.
With the upcoming market launch of Remeanagen™ and AquaKine™, XtalPi is launching a dual-track strategy: tackling R&D for major diseases while also creating consumer solutions that enhance everyday quality of life. The company will hold the molecular IP and capture a high-double-digit percentage of sales revenue, a significant return model compared to traditional drug R&D licensing.
